(Q42490495)

1 November 2017

title

Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer (English)

1 reference

1 November 2017

3

Cezary Cybulski

1 reference

1 November 2017

5

Jan Lubinski

1 reference

1 November 2017

4

Tomasz Huzarski

1 reference

1 November 2017

6

Wenancjusz Domagala

1 reference

1 November 2017

2

Dominika Wokolorczyk

1 reference

1 November 2017

1

Pawel Domagala

1 reference

1 November 2017

language of work or name

English

0 references

publication date

24 June 2011

1 reference

Breast Cancer Research and Treatment

1 November 2017

published in

1 reference

1 November 2017

volume

132

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

937-945

1 reference

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Characterization of tumor-associated Chk2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Mutations in CHEK2 associated with prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

CHEK2 variant I157T may be associated with increased breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

CHEK2 is a multiorgan cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Immunophenotypic predictive profiling of BRCA1-associated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Genomic instability in breast cancer: pathogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

Time to check CHEK2 in families with breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

CHEK2, breast cancer, and the understanding of clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1635-7

10.1007/S10549-011-1635-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 November 2017

1028515042

0 references

1 reference